BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
61.37
+2.51 (4.26%)
At close: May 12, 2025, 4:00 PM
62.00
+0.63 (1.03%)
After-hours: May 12, 2025, 7:59 PM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for BioMarin Pharmaceutical stock have an average target of 93.43, with a low estimate of 65 and a high estimate of 126. The average target predicts an increase of 52.24% from the current stock price of 61.37.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 6 |
| Buy | 10 | 10 | 11 | 11 | 11 | 10 |
| Hold | 6 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 22 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $124 → $104 | Strong Buy | Maintains | $124 → $104 | +69.46% | May 5, 2025 |
| Citigroup | Citigroup | Hold Maintains $82 → $78 | Hold | Maintains | $82 → $78 | +27.10% | May 2, 2025 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $98 | Hold → Buy | Upgrades | $98 | +59.69% | Feb 24, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $78 → $80 | Hold | Maintains | $78 → $80 | +30.36% | Feb 20, 2025 |
| Citigroup | Citigroup | Hold Maintains $81 → $82 | Hold | Maintains | $81 → $82 | +33.62% | Feb 20, 2025 |
Financial Forecast
Revenue This Year
3.20B
from 2.85B
Increased by 12.23%
Revenue Next Year
3.53B
from 3.20B
Increased by 10.12%
EPS This Year
3.26
from 2.21
Increased by 47.88%
EPS Next Year
4.13
from 3.26
Increased by 26.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.4B | 3.9B | 4.2B | ||
| Avg | 3.2B | 3.5B | 3.8B | ||
| Low | 3.0B | 3.1B | 3.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.7% | 21.4% | 20.1% | ||
| Avg | 12.2% | 10.1% | 8.0% | ||
| Low | 6.1% | -2.2% | -7.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.56 | 5.21 | 6.87 | ||
| Avg | 3.26 | 4.13 | 5.25 | ||
| Low | 2.20 | 1.08 | 3.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 106.5% | 59.6% | 66.4% | ||
| Avg | 47.9% | 26.4% | 27.3% | ||
| Low | -0.5% | -67.0% | -14.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.